{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-415559","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2026-10-06T20:07:10+00:00","discovered_at":"2026-10-06T20:08:02.422963+00:00","generated_at":"2026-10-12T16:20:51.191016+00:00","sec_items":["2.05","5.02","7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caribou Biosciences halts vispa-cel and CB-011 CAR-T programs, cuts workforce, explores strategic alternatives","bullets":["Board approved restructuring on Oct 2, 2026 with estimated charges of $15M-$19M: $10M-$11M severance/benefits and $5M-$8M to wind down the ANTLER and CaMMouflage phase 1 trials.","Majority of affected employees expected to depart in Q4 2026; Board formed a Transaction Committee and engaged Wedbush Securities Inc. as exclusive financial advisor for the strategic review.","CFO Sriram Ryali's employment terminates upon execution of a binding definitive agreement for a strategic alternative; treated as termination without cause with severance.","Cash, cash equivalents and marketable securities totaled $113.8M as of June 30, 2026; no timeline set for completing the strategic alternatives review.","Discontinued programs: vispa-cel for r/r B cell non-Hodgkin lymphoma (pivotal trial-ready, FDA-aligned phase 3 design, RMAT/Fast Track/Orphan designations) and CB-011 for r/r multiple myeloma."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-415559","json":"https://secwatch.observer/filing/0001193125-26-415559.json","markdown":"https://secwatch.observer/filing/0001193125-26-415559.md","text":"https://secwatch.observer/filing/0001193125-26-415559.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175d8k.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-12T16:20:51.191016+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"16c8d6d2f4","claim":"Sriram Ryali departed as Chief Financial Officer at Caribou Biosciences, Inc..","evidence_excerpt":"The employment of Sriram Ryali, the Company’s Chief Financial Officer, will terminate on the date the Company executes a binding definitive agreement for a strategic alternative, and such termination would be treated as a termination “without cause” under the Employment Agreement, dated January 2, 2025, between the Company and Mr. Ryali (the “Ryali Employment Agreement”).","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm","confidence":0.92,"family_label":"Executive change","details":[{"label":"Action","value":"terminate"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}